CANG vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Cango Inc. exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across nearly all health metrics. While the company shows impressive top-line revenue growth (87.9% YoY), this is completely offset by catastrophic profit margins (-90.39%) and a devastating ROE of -95.23%. Liquidity is a primary concern with a Quick Ratio of 0.25, suggesting an inability to meet short-term obligations. The stock is currently a classic 'value trap,' trading at a low Price/Book (0.38) but lacking the operational stability to justify a recovery.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CANG vs JPM: Head-to-Head Comparison
This page compares Cango Inc. (CANG) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.